NASDAQ: LQDA
Liquidia Corp Stock

$16.14-0.12 (-0.74%)
Updated Feb 13, 2025
LQDA Price
$16.14
Fair Value Price
-$11.56
Market Cap
$1.37B
52 Week Low
$8.26
52 Week High
$16.99
P/E
-9.9x
P/B
12.36x
P/S
50.17x
PEG
N/A
Dividend Yield
N/A
Revenue
$15.61M
Earnings
-$119.48M
Gross Margin
64.7%
Operating Margin
-700.79%
Profit Margin
-765.4%
Debt to Equity
1.29
Operating Cash Flow
-$89M
Beta
0.96
Next Earnings
Mar 11, 2025
Ex-Dividend
N/A
Next Dividend
N/A

LQDA Overview

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine LQDA's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More

Zen Rating Component Grades

C
Value
C
Growth
C
Momentum
C
Sentiment
C
Safety
C
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
LQDA
Ranked
#104 of 560

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important LQDA news, forecast changes, insider trades & much more!

LQDA News

Overview

Due Diligence Score

Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LQDA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

LQDA ($16.14) is overvalued by 239.66% relative to our estimate of its Fair Value price of -$11.56 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
LQDA ($16.14) is not significantly undervalued (239.66%) relative to our estimate of its Fair Value price of -$11.56 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
LQDA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more LQDA due diligence checks available for Premium users.

Valuation

LQDA fair value

Fair Value of LQDA stock based on Discounted Cash Flow (DCF)

Price
$16.14
Fair Value
-$11.56
Undervalued by
239.66%
LQDA ($16.14) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
LQDA ($16.14) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
LQDA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

LQDA price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-9.9x
Industry
-174.82x
Market
38.39x

LQDA price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
12.36x
Industry
4.78x
LQDA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

LQDA's financial health

Profit margin

Revenue
$4.4M
Net Income
-$23.2M
Profit Margin
-520.6%
LQDA's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
LQDA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$252.9M
Liabilities
$142.4M
Debt to equity
1.29
LQDA's short-term assets ($214.21M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LQDA's short-term assets ($214.21M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LQDA's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
LQDA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$25.1M
Investing
-$1.7M
Financing
$98.1M
LQDA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

LQDA vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
LQDAC$1.37B-0.71%-9.90x12.36x
VRDND$1.35B-2.58%-3.96x1.91x
FTREC$1.34B+1.97%-4.41x0.89x
ARDXC$1.34B+3.85%-18.26x8.47x
GPCR$1.39B+0.16%-11.13x1.55x

Liquidia Stock FAQ

What is Liquidia's quote symbol?

(NASDAQ: LQDA) Liquidia trades on the NASDAQ under the ticker symbol LQDA. Liquidia stock quotes can also be displayed as NASDAQ: LQDA.

If you're new to stock investing, here's how to buy Liquidia stock.

What is the 52 week high and low for Liquidia (NASDAQ: LQDA)?

(NASDAQ: LQDA) Liquidia's 52-week high was $16.99, and its 52-week low was $8.26. It is currently -5% from its 52-week high and 95.4% from its 52-week low.

How much is Liquidia stock worth today?

(NASDAQ: LQDA) Liquidia currently has 84,636,621 outstanding shares. With Liquidia stock trading at $16.14 per share, the total value of Liquidia stock (market capitalization) is $1.37B.

Liquidia stock was originally listed at a price of $11.10 in Jul 26, 2018. If you had invested in Liquidia stock at $11.10, your return over the last 6 years would have been 45.41%, for an annualized return of 6.44% (not including any dividends or dividend reinvestments).

How much is Liquidia's stock price per share?

(NASDAQ: LQDA) Liquidia stock price per share is $16.14 today (as of Feb 13, 2025).

What is Liquidia's Market Cap?

(NASDAQ: LQDA) Liquidia's market cap is $1.37B, as of Feb 14, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Liquidia's market cap is calculated by multiplying LQDA's current stock price of $16.14 by LQDA's total outstanding shares of 84,636,621.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.